Brought to you by 
Myovant Sciences nets $202mm in IPO on NYSE
18 Dec 2020
Executive Summary
Just four months after its inception, start-up Myovant Sciences Ltd. (men’s and women’s health therapeutics) netted $202mm in an initial public offering of 14.5mm shares at $15, the high end of its anticipated range, and up-sized from its original 13mm shares. This marks the largest biotech IPO so far this year.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Myovant Sciences nets $202mm in IPO on NYSE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice